ANTITUMOR ACTIVITY OF <i>ACONITUM SOONGARICUM (RANUNCULACEAE) </i>TINCTURE IN MODELS OF TRANSPLANTED LEUKEMIAS AND SOLID TUMORS
Spectrum of antitumor activity of standardised tincture from tubers of <i>Aconitum soongaricum</i> Stapf in comparison with cyclophosphamide was studied in four models of transplanted tumors in 180 female mice. <i>A. soongaricum</i> tincture administered perorally at a maximal tolerable dose (MTD) 16.3 ml/kg of body weight in dilution by the distilled water 1:10 daily within 5 days and also at a dose of 25 % from MTD daily within 30 days or 12.5 % from MTD daily till the end of a life significantly inhibited growth of the tumors: increased average life span of mice with lymphocytic leukemia P388 and lymphoid leukemia L1210 by 36 and 33 %, accordingly; reduced tumor average volume with the 45 % maximum tumor growth inhibition in mice with epidermoid Lewis lung carcinoma; reduced tumor average volume with the 47 % maximum tumor growth inhibition in mice with melanoma В16 and increased average life span of the animals by 35 %. In spite of the fact that the anti-tumor effects of <i>A. soongaricum</i> tincture was weaker compared with cyclophosphamide administered intramuscularly at a single dose of 150 or 200 mg/kg of body weight <i>A. soongaricum</i> and its separate alkaloids are perspective for creation of plant origin antitumor drug of new group.